Circulating Tumor Cells Global Market Report 2024

The circulating tumor cells market size has grown rapidly in recent years. It will grow from $10.79 billion in 2023 to $12.21 billion in 2024 at a compound annual growth rate (CAGR) of 13.1%. The growth observed in the historical period regarding circulating tumor cells (CTCs) can be attributed to several key factors. These include the rise in cancer incidence and prevalence, the clinical utility of CTCs in cancer staging processes, the emergence and growing acceptance of liquid biopsy methods, increased patient demand for minimally invasive diagnostic tests, supportive regulatory measures for liquid biopsies, and a heightened focus on early cancer detection efforts. These factors collectively contributed to the growth and recognition of the significance of CTCs during that period.

The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $19.45 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. Anticipated growth in the forthcoming period regarding circulating tumor cells (CTCs) is attributed to several factors. These encompass the increasing adoption of point-of-care CTC testing, the widespread use of microfluidic technologies in CTC analysis, a heightened focus on understanding and addressing rare types of cancer through CTC research, efforts toward standardizing CTC assays, expanding the scope of CTC-based clinical trials, and the overall economic growth, particularly in emerging markets, driving further research and development in this field. Major trends expected in the forecast period include continual innovation in CTC isolation techniques, heightened government funding allocated for CTC research initiatives, advancements in CTC detection technologies improving sensitivity and specificity, the use of liquid biopsy methods for ongoing cancer monitoring, the integration of CTC analysis with single-cell analysis for comprehensive insights, and the convergence of technological approaches integrating CTC analysis with artificial intelligence (AI) for more sophisticated analysis and interpretation of CTC data.

The growing incidence of cancer is anticipated to drive the growth of the circulating tumor cells market in the foreseeable future. Cancer, characterized by uncontrolled cell growth and spread to other parts of the body, necessitates effective early detection and diagnosis. Circulating tumor cells play a crucial role in these processes, contributing to the market's expansion. As of January 2023, the American Cancer Society Inc. reported an estimated 1.9 million new cancer cases and 608,570 cancer-related deaths in 2021. The escalating incidence of cancer is a key factor fueling the growth of the circulating tumor cells market.

The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.

Product innovations emerge as a noteworthy trend in the circulating tumor cells market, with major companies concentrating on developing innovative products to enhance their market positions. For instance, in February 2021, Menarini Silicon Biosystems, an Italy-based company specializing in liquid biopsy and single-cell technologies, introduced the CellMag CTC Epithelial Cell kit. Utilizing ferrofluid technology, this kit streamlines manual immuno-magnetic enrichment and staining of rare circulating tumor cells (CTCs). The innovative and cost-effective protocol offers standardization of sample preparation in liquid biopsy labs, reinforcing the market presence of major companies in the circulating tumor cells segment.

Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.

In April 2021 when Agilent Technologies Inc., a prominent US-based provider of software, instruments, and services for laboratory workflow, acquired Resolution Bioscience Inc. The acquisition, made for an undisclosed amount, allowed Agilent Technologies to enhance and expand its capabilities in cancer diagnostics, offering innovative technologies to cater to the evolving needs of the medical market. Resolution Bioscience Inc., the acquired company, is recognized for its expertise in developing next-generation sequencing-based oncology solutions. This strategic move signifies a commitment to advancing technologies in the field of circulating tumor cells and reinforces the market presence of major companies in the industry.

Major companies operating in the circulating tumor cells market report are Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd..

North America was the largest region in the circulating tumor cells market in 2023. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.

The circulating tumor cells market research report is one of a series of new reports that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.